Key result
Insulin-treated diabetes is linked to ~2.5-fold higher TLR risk after elective stenting vs nondiabetics.
Why the study?
The impact of diabetes mellitus, especially insulin-treated diabetes, on in-stent restenosis and clinical outcomes after coronary stent implantation was not known.
Does insulin-treated diabetes mellitus increase the risk of adverse acute and late clinical outcomes in patients undergoing elective coronary stent implantation?
Cohort (n=954)
Does insulin-treated diabetes mellitus increase the risk of adverse acute and late clinical outcomes in patients undergoing elective coronary stent implantation?
Answers are grounded in this paper and cite their sources.
Insulin-requiring diabetes mellitus is a strong independent predictor of in-hospital mortality, target lesion revascularization, and late cardiac events following elective coronary stenting, whereas non-insulin-treated diabetics have similar outcomes to nondiabetic patients.
OBJECTIVES: We compared the clinical outcomes following coronary stent implantation in insulin-treated diabetes mellitus (IDDM), non-IDDM patients, and nondiabetic patients. BACKGROUND: Diabetic patients have increased restenosis and late morbidity following balloon angioplasty. The impact of diabetes mellitus (DM), especially IDDM, on in-stent restenosis is not known. METHODS: We studied 954 consecutive patients with native coronary artery lesions treated with elective Palmaz-Schatz stents implantation using conventional coronary angiographic and intravascular ultrasound methodology. Procedural success, major in-hospital complications, and 1-year clinical outcome were compared according to the diabetic status. RESULTS. In-hospital mortality was 2% in IDDM, significantly higher (p <0.02) compared with non-IDDM (0%) and nondiabetics (0.3%). Stent thrombosis did not differ among groups (0.9% in IDDM vs. 0% in non-IDDM and 0% in nondiabetics, p >0.1). During follow-up, target lesion revascularization (TLR) was 28% in IDDM, significantly higher (p <0.05) compared with non-IDDM (17.6%) and nondiabetics (16.3%). Late cardiac event-free survival (including death, myocardial infarction [MI], and any coronary revascularization procedure) was significantly lower (p=0.0004) in IDDM (60%) compared with non-IDDM (70%) and nondiabetic patients (76%). By multivariate analysis, IDDM was an independent predictor for any late cardiac event (OR=2.05, p=0.0002) in general and TLR (odds ratio=2.51, p=0.0001) in particular. CONCLUSIONS. In a large consecutive series of patients treated by elective stent implantation, IDDM patients were at higher risk for in-hospital mortality and subsequent TLR and, as a result, had a significantly lower cardiac event-free survival rate. On the other hand, acute and long-term procedural outcome was found to be similar for non-IDDM compared with nondiabetic patients.
No takes yet. Share an insight, caveat, or question.
Abizaid et al. (1998) conducted a cohort in Native coronary artery lesions treated with elective stenting (n=954). Insulin-treated diabetes mellitus (IDDM) vs. Non-insulin-treated diabetes and nondiabetic patients was evaluated on Target lesion revascularization (TLR) (OR 2.51, p=0.0001). Insulin-treated diabetes mellitus was associated with a significantly higher risk of target lesion revascularization compared to nondiabetic patients (28% vs 16.3%; OR 2.51; p=0.0001) following elective stenting.
Synapse has enriched 10 related papers. Consider them for comparative context: